-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the iHuPBMC-B platform?
Author:
InnoModels
Release time:
2024-06-04
In the field of modern biomedicine, the importance of immune system research is self-evident. It is not only the body's first line of defense against external pathogens, but also the key to the treatment and prevention of many diseases. In order to meet the growing demand for research in this field, InnoModels Biotechnology has brought a revolutionary breakthrough in immunology research with its iHuPBMC-B platform.
The iHuPBMC-B platform is an innovative method of efficiently obtaining B lymphocytes from human peripheral blood mononuclear cells (PBMCs) based on advanced cell culture and expansion technologies. This method ensures that the resulting B lymphocytes have high activity and functional integrity, providing a more realistic and reliable cell model for research.
The primary feature of the platform is its highly efficient B lymphocyte production capacity. By fine-tuning the cell culture conditions, iHuPBMC-B is able to achieve large-scale, high-quality B lymphocyte expansion. This provides researchers with sufficient experimental materials, enabling them to explore the functions and mechanisms of B lymphocytes in immune responses in greater depth.
In addition, the iHuPBMC-B platform has a wide range of applications. It can be used not only for basic immunology research, such as B cell development, signaling, antigen recognition, etc., but also in a variety of fields, such as infectious pathology and cancer immunotherapy. By utilizing these highly efficient B lymphocytes for in vitro experiments, drug screening, and disease modeling studies, researchers can more precisely reveal the pathogenesis of diseases and provide powerful support for the development of new drugs and therapeutic strategies.

It is worth mentioning that the iHuPBMC-B platform also provides customized services. According to the specific needs of researchers, InnoModels Biotechnology can provide different types and quantities of B lymphocytes to meet the special requirements of various research projects. This personalized service approach allows researchers to better meet the specific needs of their experiments, thus improving the accuracy and reliability of their experiments.
In addition, the iHuPBMC-B platform is highly reproducible and stable. Through strict quality control standards and operational procedures, the platform ensures consistent performance and behavior of each batch of B lymphocytes. This provides researchers with reliable experimental conditions, enabling them to conduct comparable studies across laboratories and time points.
Finally, the iHuPBMC-B platform is also highly flexible and scalable. As the field of immunology research continues to evolve and deepen, the platform can be constantly updated and upgraded with new technologies to accommodate new research needs and application scenarios. This makes the iHuPBMC-B platform of Transmooker Biologicals a continuously evolving immunology research tool with broad prospects.
In summary, with its highly efficient B-lymphocyte production capacity, wide range of applications, customized services, and high degree of reproducibility, stability, and flexibility, the iHuPBMC-B platform of InnoModels Biotechnology brings unprecedented opportunities and challenges to the field of immunology research. We expect that this platform will continue to utilize its unique advantages in future research and make greater contributions to unraveling the mysteries of the immune system and advancing biomedicine.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd